Ciclesonide: a novel inhaled corticosteroid for the treatment of persistent asthma –– a pharmacologic and clinical profile. Issue 2 (March 2005)

• Record Type: Journal Article
• Authors: Berger, William E
• Is Part Of: Therapy. Volume 2:Issue 2(2005)
• Page Start: 167
• Page End: 178
• Publication Date: 2005-03
• Subjects: asthma -- ciclesonide -- desisobutyryl-ciclesonide -- efficacy -- pharmacokinetics -- safety; Therapeutics -- Periodicals; Chemotherapy -- Periodicals; 615.505
• DOI: 10.2217/14750708.2.2.167
• Languages: English
• ISSNs: 1475-0708

Abstract

Inhaled corticosteroids are recommended first-line therapy for asthma of all severities. Concerns regarding local and systemic side effects can influence adherence, and subsequently, efficacy and long-term asthma control. Ciclesonide is a novel inhaled corticosteroid with an improved therapeutic margin –– its efficacy is similar to that of other inhaled corticosteroids, but with a potentially better local and systemic safety profile in patients with persistent asthma. Ciclesonide is activated, mainly in the lung, to desisobutyryl-ciclesonide, the active metabolite, which, together with its other pharmacokinetic properties, contributes to its improved safety profile. Additionally, the drug is delivered through a hydrofluoroalkane metered-dose inhaler, which allows high lung deposition and delivery into the small airways. The improved therapeutic margin of ciclesonide may increase patient adherence, thereby ultimately improving asthma control.